• Explore /
  • Poster
  • / Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.

Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.

Abstract Poster

Authors

null

Ning Li

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China;

Ning Li , Wen-Ying Deng , Yi-Jie Ma , Liang-Yu Bie , Chi Zhang , Chen Wei , Suxia Luo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04891900

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 367)

DOI

10.1200/JCO.2023.41.4_suppl.367

Abstract #

367

Poster Bd #

F8

Abstract Disclosures

Similar Posters

First Author: Ilya Tsimafeyeu

First Author: Chenyu Mao

First Author: Xiuli Yang

First Author: Shui-Ling Jin